Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
ADVERTISEMENT FEATUREAdvertiser retains sole responsibility for the content of this article
Designing next-generation immunotherapeutics
With two established technologies, SLPs and AMPLIVANT, ISA Pharmaceuticals is developing fully synthetic immunotherapeutic vaccines to target cancer and persistent viral infections.